Trial · NCT04235062
NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure
NCT04235062, Not applicable, Completed, Momentum Research, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure. Trials, record NCT04235062. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04235062
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure
- NCT number
- NCT04235062
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 229 participants, actual
- Lead sponsor
- Momentum Research, Inc.
- Conditions
- Heart Failure
- Interventions
- Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution, Intravenous Bolus Furosemide
- First posted
- 2020-01-21
- Last updated
- 2022-04-18
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Natriuretic response to intravascular volume expansion | 2 and 3 months | The average change in natriuretic response to intravascular volume expansion from before to 2 and 3 months after initiation of sacubitril/valsartan therapy. Natriuretic response is defined as the cumulative sodium excretion over the 3 hours of intravascular volume expansion and follow up. |
| Primary | Natriuretic response to IV diuretic administration | 2 and 3 months | The average change in cumulative natriuresis during the first 3 h following the bolus IV furosemide administration from before to 2 and 3 months after initiation of sacubitril/valsartan therapy. |
| Secondary | Natriuretic peptide (NP) response to intravascular volume expansion | 2 and 3 months | Change from from before to 2 and 3 months after initiation of sacubitril/valsartan therapy in the average change over the 2-hour Ringer's infusion and follow up in plasma NP levels from just prior to the start of the infusion. |
| Secondary | Natriuretic peptide response to IV diuretic administration | 2 and 3 months | Change from before to 2 and 3 months after initiation of sacubitril/valsartan therapy in the average change in NP level from the end of the Ringer's infusion to 3 hours following the bolus IV furosemide administration |
| Secondary | Diuretic response | 2 and 3 months | Change from before to 2 and 3 months after initiation of sacubitril/valsartan therapy in the urine volume excreted over the 3 hours following the bolus IV furosemide administration |
| Secondary | 4. Changes in dyspnea as measured by a 1-10 scale in response to intravascular fluid expansion, and diuretic administration | 2 and 3 months | Change from before to 2 and 3 months after initiation of sacubitril/valsartan therapy in the average change from just prior to the Ringer's infusion start to one hour following the 2-hour Ringer's infusion and from just prior to the IV bolus furosemide administration to 3 hours following the bolus IV furosemide administration |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04235062
GET https://conductscience.org/api/trials/v1/NCT04235062/registered